Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Faes Farma
Deal Size : Undisclosed
Deal Type : Merger
SIFI Merges into Faes Farma to Expand International Access to its Portfolio and Pipeline
Details : The Group will invest into the further development of Akantior (polihexanide) into existing and new geographies, as well as the development of polihexanide into additional orphan indications.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2025
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Faes Farma
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : University of California
Deal Size : Undisclosed
Deal Type : Collaboration
SIFI, UCSF Collaborate on Acanthamoeba Keratitis Research
Details : The collaboration aims to evaluate the Akantior (polihexanide), the first and only approved drug for the treatment of AK. It is being indicated for the treatment of Acanthamoeba Keratitis in US.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 18, 2025
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : University of California
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SIFI Updates AKANTIOR® Regulatory Pathway for Acanthamoeba Keratitis in UK and US
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that got approval from european medicines agency for the treament of acanthamoeba keratitis.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SIFI Receives European Commission Approval for AKANTIOR®
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that got approval from european medicines agency for the treament of acanthamoeba keratitis.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SIFI Receives Positive Opinion for Orphan Drug Designation for Polihexanide
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SIFI Receives Positive CHMP Opinion for AKANTIOR in Acanthamoeba Keratitis
Details : Akantior® (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avanzanite’s AKANTIOR® Gets Positive CHMP Opinion and Expands into 26 European Countries
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 87% of patients receiving AKANTIOR® in the Phase 3 Trial were medically cured within a median duration of 4 months compared to 55% with the treatment protocols used in real-world clinical practice today.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Durbin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKANTIOR® (polihexanide) stands to become first approved drug for the treatment of acanthamoeba keratitis in the world. It is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Durbin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world. Polihexanide, a New Chemical Entity (NCE), is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan...
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable